Skinbiotherap. Regulatory News (SBTX)

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

Placing of shares held by major shareholder 

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, has today been informed that its major shareholder, OptiBiotix Health Plc ("OptiBiotix") has placed 3,636,363 ordinary shares in SkinBioTherapeutics with new and existing institutional investors at a price of 55 pence per share. Prior to the sale OptiBiotix held 36,138,569 ordinary shares representing 23.1% of the Company and following this sale, will continue to hold 32,502,206 ordinary shares in SkinBioTherapeutics representing 20.7% of the Company.

Optibiotix, Cenkos Securities Plc and the Company have entered into a lock-in and orderly market agreement pursuant to which Optibiotix has undertaken to the Company and to Cenkos that, subject to the customary exceptions: (i) it will not until the first anniversary of the sale dispose of the Ordinary Shares that it holds during such period; and (ii) it will only dispose of such Ordinary Shares during the 12 month period following such first anniversary through the Company's Nominated Adviser and Broker so as to ensure an orderly market in the Shares.

Stuart Ashman, CEO of SkinBioTherapeutics, said:

"We are pleased that this placing is enabling us to bring in new institutional shareholders and broadening the shareholder base in an orderly fashion. The Company is going from strength to strength with its newly launched first commercial product, AxisBiotix-Ps™, so it is important to attract new investors who are keen to come on board to support us in the next stage of the Company's development, as a commercial entity."

-Ends-

For more information please contact:

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AsixBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis was launched on 29 October - World Psoriasis Day.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotix.com .